高危B细胞急性淋巴细胞白血病患儿随机分配至不同甲氨蝶呤和皮质类固醇治疗策略后的神经认知功能:儿童肿瘤学组报告
本研究纳入192例高危B细胞急性淋巴细胞白血病患儿,随机分配至高剂量甲氨蝶呤联合亚叶酸钙救援或递增剂量甲氨蝶呤联合PEG门冬酰胺酶而不联合亚叶酸钙救援,并随机分配至地塞米松或泼尼松治疗。治疗后8至24个月进行神经认知评估,控制种族、年龄、性别、保险状态和停药时间后,甲氨蝶呤给药方式和皮质类固醇类型与神经认知结果差异无关;诊断时年龄<10岁者估算智商和加工速度得分显著低于年龄≥10岁者,持有美国公共医疗保险者估算智商显著低于持有美国私人或军队保险者。
要点
- 甲氨蝶呤给药方式和皮质类固醇类型与神经认知结果差异无关。
- 诊断时年龄<10岁者估算智商和加工速度得分显著低于年龄≥10岁者。
- 持有美国公共医疗保险者估算智商显著低于持有美国私人或军队保险者。
核心结论
- 诊断时年龄<10岁的高危B细胞急性淋巴细胞白血病患儿在未接受颅脑放疗的情况下存在智商和加工速度缺陷风险,与甲氨蝶呤给药方式或皮质类固醇类型无关。
- 这些数据可作为开发筛查方案的基础,以识别存在缺陷高风险的儿童,从而尽早启动干预以减轻治疗对神经认知结局的影响。
研究设计与样本
- 研究为儿童肿瘤学组报告,参与者随机分配至高剂量甲氨蝶呤联合亚叶酸钙救援或递增剂量甲氨蝶呤联合PEG门冬酰胺酶而不联合亚叶酸钙救援。
- 患者还随机分配至包含地塞米松或泼尼松的皮质类固醇治疗。
- 治疗后8至24个月进行神经认知评估,评估智力功能(智商)、工作记忆和加工速度(n=192)。
主要发现
- 控制种族、民族、年龄、性别、保险状态和停药时间后,甲氨蝶呤给药方式和皮质类固醇分配与神经认知结果差异无关。
- 诊断时年龄<10岁的幸存者(n=89)估算智商(P<.001)和加工速度得分(P=.02)显著低于年龄≥10岁的参与者。
- 持有美国公共医疗保险的参与者估算智商显著低于持有美国私人或军队保险者(P<.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive deficits that are associated with treatment, individual, and environmental factors. This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL. Methods Participants were randomly assigned to receive high-dose MTX with leucovorin rescue or escalating dose MTX with PEG asparaginase without leucovorin rescue. Patients were also randomly assigned to corticosteroid therapy that included either dexamethasone or prednisone. A neurocognitive evaluation of intellectual functioning (IQ), working memory, and processing speed (PS) was conducted 8 to 24 months after treatment completion (n = 192). Results The method of MTX delivery and corticosteroid assignment were unrelated to differences in neurocognitive outcomes after controlling for ethnicity, race, age, gender, insurance status, and time off treatment; however, survivors who were age < 10 years at diagnosis (n = 89) had significantly lower estimated IQ ( P < .001) and PS scores ( P = .02) compared with participants age ≥ 10 years. In addition, participants who were covered by US public health insurance had estimated IQs that were significantly lower ( P < .001) than those with US private or military insurance. Conclusion Children with high-risk B-lineage ALL who were age < 10 years at diagnosis are at risk for deficits in IQ and PS in the absence of cranial radiation, regardless of MTX delivery or corticosteroid type. These data may serve as a basis for developing screening protocols to identify children who are at high risk for deficits so that early intervention can be initiated to mitigate the impact of therapy on neurocognitive outcomes.
引用
- Hardy KK, Embry L, Kairalla JA, et al. Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. J Clin Oncol. 2017. PMID: 28671857. doi:10.1200/JCO.2016.71.7587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。